Trial Profile

An Open, Single-arm, Self-controlled, Multi-center Phase 3 Study to Compare the Efficacy and Safety of rhTSH as An Adjunctive Diagnostic Tool in Differentiated Thyroid Cancer Patients Who Had Been Thyroidectomized Vs. Patients Who After Thyroid Hormone Withdrawal

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 01 Apr 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Iodine radioactive (Primary) ; Recombinant human thyroid stimulating hormone-Suzhou Zelgen Biopharmaceuticals (Primary)
Indications Carcinoma; Thyroid cancer
Focus Registrational; Therapeutic Use
Sponsors Suzhou Zelgen Biopharmaceuticals

27 Mar 2024 Status changed from active, no longer recruiting to completed.
22 Mar 2023 Planned End Date changed from 1 Jul 2023 to 1 Jul 2024.
22 Mar 2023 Planned primary completion date changed from 1 Jun 2023 to 1 Jun 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com